IC
Ikarian Capital Portfolio holdings
AUM
$494M
1-Year Est. Return
153.64%
1 Year Est. Return
+153.64%
AUM
$302M
AUM Growth
-$4.71M
(-1.5%)
Holding
160
Top Buys
| 1 | +$10.5M | |
| 2 | +$10.1M | |
| 3 | +$8.15M | |
| 4 |
Insmed
INSM
|
+$7.95M |
| 5 |
Cogent Biosciences
COGT
|
+$7.44M |
Top Sells
| 1 | +$14M | |
| 2 | +$11.7M | |
| 3 | +$10.1M | |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$7.86M |
| 5 |
Scholar Rock
SRRK
|
+$6.91M |
Sector Composition
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Ginkgo Bioworks
DNA
$579M
| – | – |
-58,300
|
|
||
|
ELEV
152
DELISTED
Elevation Oncology
ELEV
| – | – |
-690,050
|
|
||
153
Enliven Therapeutics
ELVN
$1.59B
| – | – |
-289,538
|
|
||
154
Evolus
EOLS
$337M
| – | – |
-193,265
|
|
||
|
ETNB
155
DELISTED
89bio
ETNB
| – | – |
-100,000
|
|
||
156
Edgewise Therapeutics
EWTX
$2.9B
| – | – |
-280,000
|
|
||
157
Monte Rosa Therapeutics
GLUE
$1.81B
| – | – |
-136,575
|
|
||
158
Harrow
HROW
$1.77B
| – | – |
0
|
|
||
159
Immunovant
IMVT
$5.29B
| – | – |
0
|
|
||
160
Teladoc Health
TDOC
$1.11B
| – | – |
-150,000
|
|